European campaign to raise awareness of medical cannabis

Neuraxpharm is launching its “Change for Health” campaign in a bid to increase the acceptance of medical cannabis.

The campaign is aiming to provide better information to patients, physicians and pharmacies, and will be implemented at European level. This will start with Germany, the Czech Republic and Switzerland, and will be extended to more countries as legislation evolves.

According to the company, it will feature a video to raise awareness, a dedicated website that explains the campaign background and educational materials such as crosswords and myths and facts.

Read more: New medical cannabis education platform launched for Europe

Through the campaign, Neuraxpharm wants to encourage healthcare professionals, regulators, patients and the public to rethink preconceptions about cannabis and embrace it as an effective, individualised treatment option.

CEO of Neuraxpharm, Dr Jörg-Thomas Dierks, commented: “Medical cannabis is still a sensitive topic surrounded by prejudices. With our campaign we want healthcare professionals, regulators, patients, and the public to rethink their perception of medical cannabis and how this treatment can help millions of patients with unmet medical needs. 

Read more: UK education platform to teach Mauritius doctors about medical cannabis

“Because a change in our mindset towards medical cannabis will lead towards an improvement of patient’s health.”

Neuraxpharm will be present at the German Pain Congress with its own booth and will be sponsoring the symposium “Cannabinoids in pain treatments” to raise further awareness of this treatment approach. 

The company highlights that despite being legalised in Germany five years ago, many doctors still have reservations to prescribe medical cannabis or for patients to take it, which it suggests may be due to a lack of information. 

As a result, only one to two percent of physicians in Germany prescribe medical cannabis. Additionally, the stigmatisation of medical cannabis is still widespread and access to it for patients in need is still difficult to obtain. 

[activecampaign form=31]

• Panaxia and Neuraxpharm expand into Czech and Swiss markets
• Panaxia and Neuraxpharm to bring medical cannabis products to Poland
• Health benefits of cannabinoids driving US market
• Urgent need for unified regulatory approach to cannabis contamination in US
• Groundbreaking agreement to supply Czech patients with cannabis extracts